Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TulmiSTAR-02 in metastatic hormone-sensitive prostate cancer
CTR20254909Phase 2Active
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tulmimetostat, darolutamide, abiraterone in prostate cancer (PCa), sponsored by Novartis. Started Feb 2026; status: active.
02
Drugs
tulmimetostatdarolutamideabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20254909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254909.